~ Positive Enrollment Progress and Safety Data ~

~ FDA Attention Establishes Momentum in the Pain Treatment Space ~

Integrated Healthcare Association's Excellence in Healthcare Award Recognizes Provider Organizations for Achieving Top Marks Simultaneously on Quality, Patient Experience, and Cost

Minicarm.com: Your Go-To Source for Hologic Fluoroscan Mini C-Arm Sales, Parts & Service

Dr. Anni Wong discusses approaches to effectively treat facial keloids and improve patient outcomes in Monroe Township and Freehold.

This announcement underscores Dr. Shervin Naderi's dedication to delivering exceptional care and achieving outstanding results for his patients. As a 2025 Castle Connolly Top Doctor, Dr. Naderi continues to set the standard for excellence in facial plastic surgery, inspiring confidence and trust among patients nationwide.

With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to stimulate hair follicle formation and promote sustained hair growth.

EnvisionOne Vantage enables medical affairs professionals to benchmark their publication performance against other companies, providing crucial competitive intelligence and valuable insights for strategic adjustments to publication strategies.

Long COVID patient finds hope, and help through The Spero Clinic's neurological relief program.

Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Hypoparathyroidism

Gut-Brain Longevity Health Company bringing Patented Postbiotic for Functional Foods

Ranked #1 in EHR & Digital Health Solutions by Black Book Research surveys of nearly 28,000 global EHR users-Leading Innovation Across All Spanish-Speaking Latin American Countries, Germany, Austria, Switzerland, Liechtenstein (DACHL), Portugal, the UK, and Italy with AI, Cloud, and Interoperability.

Localized Innovation Reshaping Digital Healthcare: Insights from Black Book's 2025 EHR Market Survey Covering Two-Thirds of Global Vendors

Global logistics expansion and alternative solutions help medical OEMs maintain momentum.

Beiersdorf Sponsors Top Dermatology Residents to Attend the 2025 Maui Derm-Hawaii Conference

In-Home Consumer Harvests Increase Exponentially After Research Discovery at Hypha Laboratories

Seasoned leader will support Vytalize Health's physician partners in delivering holistic, patient-centered care that enhances outcomes and strengthens patient-doctor relationships

- Engaged BSI Group to start the process of obtaining regulatory clearance of the MODD1, next-generation insulin pump for the European market

- Targeting Q1 2026 for expected clearance of the MODD1 in the E.U.

Funding from the NIH's National Institute on Drug Abuse (NIDA) will Support Development of ENA-001, an Agnostic Respiratory Stimulant, for Community Drug Overdose and as a Medical Countermeasure

ASCCP and NCI Publish Guidance in the Journal of Lower Genital Tract Disease; BD Onclarity HPV Assay Identifies Risk by HPV Type for Tailored Management

Englewood Health sought an innovative cloud Enterprise Imaging Platform that could streamline clinical and administrative operations, and relieve current and future system infrastructure needs. They found that solution along with an alliance with the ideal partner, AGFA HealthCare.

Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported in up to 85%

Crofelemer, approved by the FDA under the brand name Mytesi^® for HIV-related diarrhea, has demonstrated a significant benefit in improving gastrointestinal symptoms, including diarrhea, abdominal pain and discomfort, incontinence, bloating and constipation, when studied in populations with HIV-related diarrhea, cancer therapy-related diarrhea, and IBS

- This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne -

- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ clinical trial in March 2025 -

- Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy -

New document compares vaccine risks to 10 disease risks

A range of clinical topics will be covered throughout the year at the in-person events held in Southern California.

Empowering healthcare IT departments to experience Grow, Work, and Life - In Balance, with AGFA HealthCare's unified, purpose-built, modern Enterprise Imaging Platform.

2025 list recognizes leading health systems, hospitals and physician practices